Bisphosphonates, analogues of pyrophosphate, are potent inhibitors of osteoclast-mediated bone resorption. They are used in the treatment of Paget's disease of bone, hypercalcaemia and osteolytic bone disease of malignancy, primary and secondary hyperparathyroidism,and in osteoporosis. Bisphosphonate treatment causes an early reduction in bone resorption followed by a later reduction in bone formation. The early inhibition of bone resorption induces a reduction in serum calcium which leads to increased parathyroid hormone (PTH), and subsequently an increase in 1,25-dihydroxyvitamin D. The secondary hyperparathyroidism of bisphosphonate treatment also leads to urinary calcium conservation and phosphaturia, and a reduction in serum phosphate. The increase in the PTH following bisphosphonate therapy is a response to the change in serum calcium and can occur even when there is hypercalcaemia, and this can cause confusion in the interpretation of PTH results. The hypocalcaemic response to bisphosphonates is occasionally severe, especially in patients with hypoparathyroidism. The recent elucidation of bisphosphonate action at the cellular level on the mevalonate pathway has led to interest in its effects on lipoprotein metabolism, which may prove to be of clinical signi®cance. Newer and more potent bisphosphonates are currently undergoing clinical trials in malignant bone disease and osteoporosis, and will lead to further advances in the optimal management of these conditions.
Bisphosphonates are a family of drugs that have been used in the management of disorders of calcium and bone metabolism for the last three decades. They are of added interest to the clinical biochemist because of their signi®cant impact on serum and urine biochemistry. Bisphosphonates are analogues of pyrophosphate (P i ± O± P i ) and are characterized by two carbon-phosphate bonds (P i ± C± P i ; Fig. 1 ). They have a marked af®nity for solid-phase calcium phosphate and bind to crystal surfaces to inhibit crystal growth in vitro. When given in large enough doses bisphosphonates, like pyrophosphate, inhibit normal and ectopic mineralization in vivo. Unlike pyrophosphate, which can be cleaved by enzymatic hydrolysis, the P± C± P bond in bisphosphonates is resistant to hydrolysis. 1 The therapeutic potential of bisphosphonates is due to their potent inhibition of osteoclast-mediated bone resorption. Different substitutions of the two hydrogens on the carbon atom have led to the synthesis of many different bisphosphonates, each with its distinct physical, chemical, biological, therapeutic and toxicological characteristics ( Fig. 1 ). 2 The potency of inhibiting bone resorption varies between the different bisphosphonates by up to 5000-fold (Table 1) , the antiresorptive potency probably being dependent on the side-chain structure of the different bisphosphonates.
In vitro, bisphosphonates inhibit osteoclastmediated bone resorption stimulated by a variety of osteotropic agents, including parathyroid hormone (PTH), calcitriol, prostaglandins and bone-resorbing cytokines. Bisphosphonates are used in a number of disorders characterized by increased bone resorption, namely Paget's disease of bone, hypercalcaemia and osteolytic bone disease of malignancy, primary and secondary hyperparathyroidism, and more recently in osteoporosis. The clinical and commercial interest in bisphosphonates has been stimulated recently by the realization of the extent of prevalence of osteoporosis and the ef®cacy of bisphosphonates in fracture prevention. At a scienti®c level, the emerging data on their mechanism of action and their effects in malignant disease make this a fascinating class of drugs to study.
The following bisphosphonates are currently in clinical use: etidronate, clodronate, pamidronate, alendronate, risedronate, ibandronate and tiludronate. Many others are being investigated for use in human bone disease, e.g. neridronate, olpandronate, cimadronate, incadronate and zoledronate. Other bisphosphonates have been tested only in animals.
MECHANISM OF BISPHOSPHONATE ACTION
Like pyrophosphate, bisphosphonates bind strongly to hydroxyapatite crystals and also inhibit crystal dissolution. The preferential accumulation of bisphosphonates in bone and their inhibitory effect on bone resorption were initially thought to be related to this action. However, recent data point to a cellular mechanism for the antiresorptive action of bisphosphonates. 4 It is now generally accepted that the main cell by which bisphosphonates mediate their action is the osteoclast. Four mechanisms are postulated for their action on osteoclasts: inhibition of osteoclast recruitment, inhibition of osteoclast adhesion, shortening of osteoclast lifespan (apoptosis), and inhibition of osteoclast activity. 5 However, bisphosphonates have been shown to have inhibitory action on osteoblasts, macrophages and tumour cells as well.
The direct effects of bisphosphonates on osteoclasts seem to depend on the bisphosphonate being previously adsorbed on to bone. The bound bisphosphonate can be released by acidi®cation of the sealing zone of the osteoclasts. 6 Bisphosphonatesare taken up by cells, and can enter cells of macrophage lineage under certain conditions. 7,8 Studies in the amoeba Dictyostelium discoideum suggest that bisphosphonates, which inhibit their growth by mechanisms similar to the inhibition of osteoclasts, are internalized by these organisms, and amoebae that were prevented from internalizing bisphosphonates were resistant to their effects. 9 These data also suggest that bisphosphonate effects on osteoclasts are mediated by interaction with intracellular rather than extracellular processes. A number of intracellular biochemical effects have been demonstrated in vitro for bisphosphonates, including effects on glycolysis, lysosomal enzyme production, prostaglandin synthesis and, in osteoclasts, decrease in acid production. 10,11 Effects on membrane permeability have also been demonstrated in osteoclasts and may account for structural changes observed at their ruf¯ed border and cytoskeleton. 6, 12 Bisphosphonates were generally thought not to be metabolized in vivo. However, recent in vitro studies have shown that mammalian cells can metabolize clodronate (but not alendronate) to a non-hydrolysable adenosine triphosphate (ATP) analogue, which could explain its toxic effects on cells. 13 On the other hand, alendronate, and possibly other nitrogencontaining bisphosphonates, prevents protein prenylation in osteoclasts by inhibiting enzymes of the mevalonate pathway required for the synthesis of farnesyl pyrophosphate or geranylgeranyl pyrophosphate. 14±16 These results, then, suggest that different groups of bisphosphonates may act by different mechanisms. The end result of bisphosphonate action is that the functional performance of the osteoclasts is decreased.
There is also evidence that bisphosphonate action may be mediated partly through cells other than osteoclasts, and that osteoblasts may have a role in the inhibition of bone resorption by these drugs. Bisphosphonates have been postulated to induce osteoblasts to secrete an inhibitor of osteoclastic resorption. 17 They also inhibit alkaline phosphatase secretion and the proliferation of isolated human osteoblasts. 18 The low concentration threshold for bisphosphonate activity points to a receptor or a cellular binding site, which induces a cellular transduction mechanism. 19 This putative receptor has not yet been identi®ed, but because bisphosphonates enter the cell via pinocytosis the latter could be an intracellular enzyme, a pump, or a protein involved in the cell signalling cascade. Cells of the mononuclear phagocyte system and of the immune system may be alternative mediators of the bisphosphonate effect on osteoclasts, via the cytokines they produce.
In conclusion, the inhibitory effect of bisphosphonates on bone resorption is probably mediated by different mechanisms, affecting both the recruitment of osteoclast precursors and the activity of mature osteoclasts. Clearly, current knowledge about these mechanisms is incomplete.
PHARMACOKINETICS OF BISPHOSPHONATES
Oral bisphosphonates are poorly absorbed, with 1% or less of the administered dose being taken up. Absorption is almost entirely prevented by the presence of food containing calcium or other divalent ions which chelate the bisphosphonate. Therefore, the drug is taken away from food. 20, 21 On the other hand, the administration of EDTA, which chelates calcium, increases the absorption of bisphosphonates. 22 Absorption is also increased by an increase in the intraluminal pH, e.g. H 2 receptor antagonist therapy. 23 Following intravenous infusion alendronate is rapidly cleared from plasma, with 40% of the dose being excreted as the parent compound in urine within 24 h; it is not metabolized in the body. 24 Although alendronate is highly bound to plasma proteins, limiting renal excretion, renal clearance ± 50% of glomerular ®ltration rate (GFR) ± is greater than the product of GFR and the unbound fraction in plasma, indicating signi®cant tubular secretion of the drug. A small fraction of alendronate is excreted into bile; the rest is rapidly taken up mostly by bone. 25±27 Although generally the resorption surface in bone bears the highest concentrations, in pathological conditions, especially multiple myeloma, technetium-99 ( 99m Tc)-labelled bisphosphonate is not taken up by foci of bone resorption. The targeting effect of administered bisphosphonates to resorbing bone surfaces is of clinical bene®t in that most of the drug is delivered to the site of the disorder, thereby sparing non-affected sites.
Terminal elimination half-life for alendronate in humans has been estimated at 12 years. 24 The question of whether the bisphosphonate that accumulates in the skeleton has a cumulative effect on bone metabolism is important. Current data suggest that bisphosphonate that gets buried in bone tissue is not biologically active, and it is probable that only the drug that is bound to bone surface is active. Because alendronate taken up by bone is soon buried inside subsequently formed bone tissue, continuous or frequent administration of the drug may be required for sustained inhibition of bone resorption. 6,28,29
BISPHOSPHONATE ACTION IN OSTEOPOROSIS
Osteoporosis is characterized by a reduction in bone mass owing to the attainment of a low peak bone mass and/or accelerated bone loss resulting from an imbalance between bone resorption and formation. In health, an equal amount of bone is formed as is lost in each bone multicellular unit (BMU), resulting in zero balance. Bone resorption and formation are coupled in that, when resorption is increased, bone formation is also increased. In osteoporosis, although resorption and formation are still coupled, there is an imbalance between the two in that the amount of bone formed in each BMU is less than the resorbed bone, resulting in negative balance. When there is net de®cit of newly formed bone in each BMU and also an increase in the number of BMUs, the rate of bone loss due to the imbalance between formation and resorption is accelerated.
The primary effect of bisphosphonates is to reduce bone resorption: i.e. there is a reduction in the number of newly formed BMUs. Initially when this occurs bone formation continues in the previously formed BMUs, but once they are ®lled in there is a reduction in bone formation rate at the tissue level, as there are fewer resorption cavities to be ®lled. Therefore, the reduction in bone formation following bisphosphonate therapy is delayed, whereas inhibition of bone resorption occurs almost immediately. This temporary imbalance between formation and resorption (remodelling transient) gives rise to a small but ®nite increment in bone density, which may be bene®cial in osteoporosis.
However, once the reduction in bone formation`catches up' with the reduced bone resorption, the bone mass would be expected to start decreasing again, albeit at a slower rate than in the pretreatment state, unless bisphosphonates also affect the balance between bone resorption and formation. The decrease in the rate of bone loss itself may be useful by delaying the attainment of the fracture threshold. The transient increase in bone density may last for up to 3 years.
An additional mechanism that has been suggested for the increase in bone density following bisphosphonate therapy is that the slower remodelling rate allows mineralization to continue for several years. 30 This will lead to an increase in bone density due purely to more complete mineralization (secondary mineralization), rather than to an increase in bone volume.
In addition, there is histological evidence to suggest that bisphosphonates may in fact reduce the depth of resorption cavities. 31±33 If bisphosphonates are capable of decreasing the depth of erosion cavities by suppressing osteoclast activity within each BMU, then the imbalance between resorption and formation so characteristic of osteoporosis can in fact be reversed.
There are also data to suggest that bisphosphonates may additionally cause stimulation of bone formation, leading to an increase in the amount of bone formed in individual BMUs. 34±37 This is supported by clinical evidence which suggests that long-term bisphosphonate treatment may in fact give rise to continued increases in bone mass. 38 Longer-term follow-up studies that are properly designed to answer this question clinically should settle this issue.
Etidronate was the ®rst bisphosphonate to be used for the treatment of osteoporosis. Two randomized double-blind trials using cyclical etidronate (400 mg daily for 2 weeks every 3 months) in women with post-menopausal osteoporosis and vertebral compression fractures reported a decrease in vertebral fracture frequency at 2 years. 39, 40 There are now some epidemiological data to suggest ef®cacy of cyclical etidronate therapy in reducing the incidence of hip fractures as well. 41 Oral alendronate 10 mg daily is used as continuous therapy for the treatment of osteoporosis. Conclusive data are now available for the ef®cacy of alendronate in fracture prevention in post-menopausal osteoporosis. Liberman et al. 42 published data from their randomized, doubleblind placebo-controlled trial in 994 women treated with continuous oral alendronate for 3 years. Alendronate therapy resulted in a 48% reduction in the proportion of women with new vertebral fractures and a reduction in the number of new fractures, in addition to progressive increases in bone density at the spine and hip over that period. The Fracture Intervention Trial was the ®rst to show de®nitive evidence of the ef®cacy of bisphosphonate in the prevention of non-vertebral fractures. 43 In the pre-existing vertebral fracture arm of the study 2027 postmenopausal women were randomized to continuous oral alendronate or placebo. Alendronate therapy resulted in a 51% reduction in hip fracture risk. A similar 48% reduction in risk of wrist fracture was also shown. Results from the other arm of the study involving women without a previous fracture showed that continuous oral alendronate therapy reduced vertebral fractures in women with low bone density, and also reduces the risk of clinical (non-vertebral) fractures in women with osteoporosis. 44 The main drawback in oral alendronate therapy is the risk of oesophagitis. In fact, intravenous alendronate given intermittently may be a useful alternative, 45 although the intravenous form of alendronate is not available for use in most countries. The use of intermittent therapy with bolus intravenous injections every 12 months of a newer and very potent bisphosphonate zoledronate shows promise.
Residronate 5 mg daily has also been shown to have similar ef®cacy to alendronate in vertebral and non-vertebral fractures, including reducing the risk of hip fracture. 46±48 Intermittent oral therapy may be an alternative to continuous daily therapy with alendronate (70 mg once weekly 49 ) and risedronate (30 mg/day for 2 out of 12 weeks 50 ).
The changes that occur in markers of bone remodelling with bisphosphonate therapy have been well characterized. Hydroxyproline in early-morning fasting urine, which was used as a marker of bone resorption, has now generally been replaced by assays in urine for deoxypyridinoline (Dpd) or type 1 collagen telopeptide breakdown products (NTX and CTX). Although all the above resorption markers in urine respond in a similar manner following bisphosphonate therapy, they differ in the magnitude of response as well as their sensitivity and speci®city. Following the institution of treatment with bisphosphonates for osteoporosis, there is an early reduction in bone resorption markers ± within days following intravenous therapy 45 and within weeks following oral therapy. 51 NTX in urine decreased by 50±65% within 4 weeks of starting oral alendronate therapy, and remained low for the duration of therapy. 51±53 The percentage reduction in urinary total Dpd measured by HPLC seems to be less than that of NTX and CTX, 54 and the reduction in urinary free Dpd measured by immunoassay seems to be even less, at around 10±30%. 52, 53 It has been suggested that NTX and CTX in urine are more speci®c markers of the response of bone resorption to bisphosphonate therapy in osteoporosis compared to total and free Dpd. 54, 55 Clearly, NTX and CTX are more responsive bone resorption markers than free Dpd in urine. 56 However, the impact of the dayto-day variability of resorption markers on their utility for monitoring individual patients has to be taken into account. 57±59 For example, the total intra-individual variations in NTX and CTX are larger than that of free Dpd in urine, making minimum signi®cant change larger for the former. 60 Rosen et al. found that NTX and free Dpd showed a decrease exceeding the least signi®cant change in 57% and 48% patients respectively, following bisphosphonate therapy. 60 Alternatively, the reduction of resorption markers into the pre-menopausal range or an evidence-based decision limit may be aimed for. For example, a therapeutic goal of <38 nmol/L bone collagen equivalents/mmol/L creatinine has been recommended for urine NTX based on optimum bone density change following hormone replacement therapy. 61 Early changes in NTX and CTX at 6 months have been shown to predict long-term response to bisphosphonate therapy in terms of bone density in studies with alendronate. 52, 62 The measurement of bone resorption markers in blood is being trialled and may prove to be advantageousin monitoring bone resorption if their day-to-day variation is signi®cantly smaller.
The bone formation markers osteocalcin and alkaline phosphatase (ALP), which are measured in serum, have smaller day-to-day variations, and therefore smaller changes would be signi®cant in individual patients following bisphosphonate therapy. 57, 60 Although total ALP is often used in evaluating and monitoring osteoporotic patients without liver disease because of its ease of measurement and low cost, bone-speci®c ALP (B-ALP) is more speci®c for bone and therefore more sensitive in detecting the small changes in bone formation seen in osteoporosis. Rosen et al. found that the marker that most often showed a signi®cant decrease in patients treated with bisphosphonates was B-ALP (74% of patients). 60 Garnero and Delmas found that both the B-ALP level and the percentage change from baseline at 6 months of alendronate treatment correlated with the increase in bone density 2 years after treatment. 63 They have suggested a model using both these parameters of B-ALP, whereby nonresponders can be identi®ed with 90% speci®city and 72% sensitivity. 63 Osteocalcin is often suggested to be a good marker of bone formation, especially in steroidinduced osteoporosis. However, steroids directly downregulate osteocalcin gene expression, and it is unclear how this confounds the utility of serum osteocalcin in this context. The changes in serum osteocalcin following bisphosphonate therapy in post-menopausal osteoporosis are similar to those of B-ALP 51, 53 (Fig. 2) .
The potential bene®t of using bone remodelling markers to monitor bisphosphonate therapy is that the response to therapy can be observed earlier than with bone density measurement (3±6 months as opposed to 1±2 years). However, because of questions over their sensitivity, speci®city and predictive value, and lack of consensus on their optimum use, routine monitoring of bisphosphonate with bone remodelling markers has not been generally recommended. 65 However, their use in epidemiological studies and drug trials is clearly accepted. 59
PAGET'S DISEASE OF BONE
Serum ALP and urine excretion of hydroxyproline, Dpd, NTX and CTX are raised in active Paget's disease, the concentrations being proportionate to disease activity and extent. Total ALP is usually adequate for assessing bone formation in Paget's disease. However, it must be noted that the concentrations of these markers in active localized or mono-osteotic Paget's disease may be within the population reference range, although raised for the particular patient. Osteocalcin has been found not to re¯ect bone formation activity in Paget's disease and is thus not a useful marker in this condition.
Bisphosphonates are the drugs of choice in Paget's disease when treatment is indicated. Their primary action is to suppress bone resorption, which is re¯ected in an early reduction in the excretion of resorption markers (Fig. 3 ). This reduction occurs within days to weeks. The response is earlier with intravenous bisphosphonate than with the oral form. With intravenous pamidronate or alendronate, a plateau is usually reached by 3 months after the infusion. With oral forms, therapy is usually given for 3±6 months or more, and a plateau may not be reached until after cessation of therapy. The magnitude of reduction in the excretion of free DPD and the peptide-bound crosslinks (NTX and CTX) in response to bisphosphonates varies, with peptide-bound crosslinks showing greater response than free Dpd. 54 It is unclear whether this differential response is because NTX is more bone-speci®c than free Dpd. An alternative explanation is that the proportion of peptide-bound crosslinks may be increased in high bone turnover states, due partly to a rate-limiting step in their degradation to free crosslinks. 66 According to this model, conditions with high bone resorption rates would have high levels of NTX that would decline rapidly when resorption rates fall to a level where the capacity to degrade NTX matches the rate of production. Another factor which may in part explain this discrepancy but which has not been fully elucidated, is the renal handling or metabolism of peptide-bound crosslinks. 67 The reduction in resorption markers with bisphosphonate treatment is followed by a later decline in serum ALP, which also reaches its nadir or plateau later than the resorption markers (Fig. 4) . The decreases in serum ALP and urine resorption marker excretion are correlated with each other. The majority of patients normalize their biochemical markers following treatment with an adequate dose of bisphosphonate, con®rming remission of disease activity. The suppression of the increased bone remodelling activity in Paget's disease by bis-phosphonates is associated with improvements in the clinical and radiological manifestations of the disease. Patients with biochemical markers that do not normalize with treatment usually have more active or extensive disease, and further treatment with the same bisphosphonate or with a more potent one may be indicated. It has been suggested that some patients develop resistance to repeated treatments with the same bisphosphonate, and that they may show better response to an alternative one. 68 Remission may last many months to many years, and relapse of disease activity is indicated by an increase in the markers of bone remodelling; these markers are used to follow-up pagetic patients in remission following treatment. Patients whose markers normalize after treatment remain in remission longer than those in whom the markers do not normalize. 69 Although etidronate has been used for three decades, its dose is limited by concerns about its causing mineralization defects in bone.
Although the 400 mg daily dose in a 6-month-on and 6-month-off cycle is adequate for mild to moderate disease, it may not be effective in extensive osteolytic disease. Alendronate, risedronate and tiludronate orally and pamidronate as an intravenous infusion have also been used in the treatment of Paget's disease. Clinical trials that evaluated oral alendronate therapy in Paget's disease have con®rmed the safety and ef®cacy of the 40 mg daily dose for 6 months. 70, 71 From about a half to two-thirds of patients normalize their ALP after 6 months of treatment. Although the recommended dose for this condition is 40 mg daily, a higher dose ± 80 mg daily ± may lead to biochemical remission in a larger proportion of patients. 72 The dose for oral risedronate in Paget's disease is 30 mg daily. 73, 74 Newer and more potent drugs, such as ibandronate and zoledronate, are also being evaluated in Paget's disease. 75 
HYPERCALCAEMIA OF MALIGNANCY
The use of bisphosphonates in the treatment of hypercalcaemia of malignancy is well established. Hypercalcaemia of malignancy is multifactorial in origin. Increased bone destruction due to the tumour itself, increased renal tubular reabsorption of calcium mediated by PTHrelated peptide (PTHrP), dehydration and, less commonly, elevated 1,25-dihydroxy vitamin D and decreased bone formation (uncoupled bone resorption) are some of the mechanisms implicated. Rehydration is an effective and important ®rst step in the management of hypercalcaemia and, together with saline diuresis if necessary, may resolve mild hypercalcaemia without other forms of treatment. The action of bisphosphonates is on the ®rst of the above-mentioned mechanisms, namely to reduce bone resorption. Therefore, bisphosphonates are most effective in correcting hypercalcaemia induced by osteolytic malignancies, and less so in other situations (e.g. humoral hypercalcaemia of malignancy) as they do not counteract the increased renal reabsorption of calcium induced by PTHrP. Intravenous infusion of pamidronate 60±90 mg as a single dose or 30±60 mg daily over a few days is commonly used, depending on the severity of disease. Treatment normalizes serum calcium for several days to weeks in 70±100% of patients, although its onset of action is delayed for 1±2 days. Treatment needs to be repeated when hypercalcaemia recurs. Clodronate is an alternative bisphosphonate which may be given intravenously ± 300 mg daily for 5 days or a single infusion of 1500 mg ± as well as in the oral form. Oral bisphosphonate (e.g. clodronate 1600±3200 mg daily) may be used in long-term therapy of hypercalcaemia. The newer bisphosphonates ibandronate and zoledronate, given intravenously, have also been shown to be effective in the treatment of hypercalcaemia of malignancy. 75
MALIGNANT BONE DISEASE
There have been major developments over the last few years in the use of bisphosphonates for tumour-induced bone disease, to reduce skeletal events and bone pain. The two main areas of promise are multiple myeloma and breast cancer. Multiple myeloma patients treated with 90 mg of pamidronate as a monthly infusion in addition to standard chemotherapy have sig-ni®cantly fewer pathological fractures, spinal cord compressions or interventions on bone (surgery or irradiation), than those who receive standard treatment alone. 76 Monthly pamidronate infusions are now standard adjuvant therapy for multiple myeloma. There is also evidence for the ef®cacy of oral clodronate in reducing skeletal events and pain in multiple myeloma. 77, 78 In breast cancer too, intravenous pamidronate has been shown to reduce morbidity by slowing the progression of bone metastases, reducing pathological fractures and reducing the need for radiation or surgery to treat bone complications. 79±81 Likewise, clodronate has been shown to reduce the development of new bony metastases in patients with breast cancer, as well as the number of skeletal events in patients with metastatic breast cancer. 82, 83 The above studies have even shown survival advantages with bisphosphonate treatment in subsets of patients with multiple myeloma and breast carcinoma, but not for the entire group treated.
Even more intriguing data in this area were published recently suggesting that oral clodronate signi®cantly reduces the incidence of metastases not only in bone but also in soft tissue in patients with breast cancer. 84 There are other supporting data for an effect of clodronate on tumour burden in soft tissue. 85 The mechanisms for the antitumour action of bisphosphonates are unclear, but both direct action on the tumour cells to induce apoptosis and indirect action by altering the microenvironment in which the tumour cells grow, have been postulated. 86 The effects of the more potent bisphosphonates in osteolytic bone disease are currently being evaluated. 87
PRIMARY HYPERPARATHYROIDISM
In primary hyperparathyroidism the elevated PTH increases osteoclastic bone resorption, renal tubular reabsorption of calcium, and stimulates the formation of 1,25-dihydroxy vitamin D, which increases intestinal calcium absorption. Bisphosphonates that inhibit osteoclast activity would thus only affect one of the many sites of PTH action. 88 However, bisphosphonate therapy may be useful in some situations, such as in acute hypercalcaemic crises, when saline rehydration has not normalized serum calcium. 89 Bisphosphonate treatment in primary hyperparathyroidism should, however, be considered a temporary measure prior to surgery. The de®nitive treatment of primary hyperparathyroidism is surgery to remove the parathyroid adenoma or the hyperplastic glands, as the case may be. 90 Long-term treatment with bisphosphonates often results in the recurrence of hypercalcaemia, as there is a secondary increase in PTH secretion in response to the reduction in serum calcium. 89 Bisphosphonates are, however, useful in treating the bone disease of primary hyperparathyroidism, leading to normalization of markers of bone turnover and maintenance or improvement of bone density. 91, 92 
OSTEOGENESIS IMPERFECTA
There is evidence that the bisphosphonate therapy may be useful in the treatment of osteogenesis imperfecta, a condition characterized by defective bone formation. 93 This is all the more intriguing in that the principal action of bisphosphonates is suppression of bone resorption.
EFFECTS ON CALCIUM AND PHOSPHATE METABOLISM
The acute effects of bisphosphonates on serum calcium and phosphate homoeostasis have been well characterized. 94, 95 Serum calcium and PTH are usually within the reference range in osteoporosis, and in Paget's disease except when these patients are immobilized. During treatment with bisphosphonates, the early inhibition of bone resorption induces a decrease in serum calcium (Fig. 5 ) which stimulates the secretion of PTH 95±97 (Figs 6 and 7) . The reduction in serum calcium occurs within days to weeks of the start of treatment ± earlier with intravenous therapy than with oral treatment. These changes may persist for many weeks to months following the initiation of treatment, and may be prominent in vitamin D-insuf®cient patients. Fasting urinary calcium excretion is usually raised in patients with active Paget's disease, and following treatment with bisphosphonates it normalizes because of the reduction in calcium release from the bone, as well as the increased renal tubular reabsorption due to increased PTH (Fig. 8 ). In osteoporosis also there is a reduction in urine fasting calcium excretion with bisphosphonate therapy. The reduction in TmP/GFR and serum phosphate that follows treatment with bisphosphonates is attributed to the secondary hyperparathyroidism. 98, 99 However, clodronate has been shown to induce a transient but signi®cant increase in serum phosphate and renal tubular reabsorption of phosphate in Paget's disease before these measurements decrease signi®cantly to below pre-treatment values. 98, 100 In hypoparathyroid patients who are unable to mount a PTH response, bisphosphonates have been shown to induce a marked and sustained increase in serum phosphate and renal tubular reabsorption of phosphate 98, 99 (Fig. 9) . In contrast to the other bisphosphonates, high doses of etidronate by intravenous infusion or by mouth do not decrease serum calcium or phosphate in Paget's disease of bone. 101 The likely reason is that high doses also inhibit the mineralization of bone, and the impairment of mineral accretion offsets the effects of decreased bone resorption on serum calcium. 100 Also, etidronate induces a dose-dependent increase in serum phosphate because of an increase in renal tubular reabsorption of phosphate. 102 This suggests that bisphosphonates other than etidronate act directly on renal tubules to increase phosphate reabsorption, but that this action is usually overridden by the secondary hyperparathyroidism. The mechanism by which bisphosphonates increase renal tubular reabsorption of phosphate has not been elucidated.
The hypocalcaemic response to bisphosphonates mentioned above, although usually mild, can occasionally be severe enough to be symptomatic and warrant clinical intervention.
Most reports of symptomatic hypocalcaemia have involved cancer patients presenting with paraesthesiae and tetany a few days to a fortnight after treatment with intravenous bisphosphonates. 103, 104 Patients with hypoparathyroidism would be especially at risk of this complication, as they would not be able to counteract the hypocalcaemic effects of bisphosphonate action.
BISPHOSPHONATES AND LIPOPROTEINS
The recent demonstration that amino-bisphosphonates act via the mevalonate pathway 14±16 has led to speculation that these drugs may have an effect on cholesterol synthesis and blood lipid concentrations. There are some data to suggest that the bisphosphonate etidronate, a nonamino-bisphosphonate, may have a bene®cial effect on the atherosclerotic process, although it has no effects on serum lipid concentrations. 105 Neridronate, and possibly other amino-bisphosphonates, when given intravenously, have a bene®cial effect on serum lipoprotein concentrations, with increases in HDL cholesterol and apo A1, and decreases in LDL cholesterol and apo B. 106 Studies in the author's laboratory suggest that oral alendronate 40 mg daily has no effect on serum lipoproteins, whereas infused pamidronate 60 mg leads to a reduction in fasting triglycerides and an increase in HDL cholesterol (unpublished data). These early data suggest that amino-bisphosphonatesgiven intravenously have a bene®cial effect on serum lipoprotein pro®le, but not when given orally. Properly designed studies are needed to con®rm these exciting early data and to examine the effects of bisphosphonates on the atherosclerotic process.
SIDE-EFFECTS
A transient fever and a¯u-like illness attributable to an acute-phase reaction have been described with bisphosphonate therapy. The reaction is well described with intravenous alendronate and other amino-bisphosphonates, and has been proposed to be mediated by interleukin-1. 107, 108 The acute-phase reaction is usually associated with the ®rst exposure to the amino-bisphosphonate and not subsequent exposures, which is thought to be due to the macrophages becoming refractory to the effects of bisphosphonates.
CONCLUSION
Bisphosphonates are a family of drugs with potent antiresorptive action on bone and proven ef®cacy in the treatment of osteoporosis, Paget's disease of bone and malignant bone disease, including hypercalcaemia of malignancy. Their widespread use in patients with metabolic bone disease, and their effect on calcium and parathyroid homoeostasis, make them an important family of drugs from the clinical biochemist's point of view. Better understanding of the cellular and molecular actions of bisphosphonates in malignancy in the future will further enhance their targeted and more effective use in these conditions. The development of more potent bisphosphonates for routine use in osteoporosis and Paget's disease should improve their ease of use and safety. The elucidation of the mechanism of action of amino-bisphosphonates, which is mediated via the mevalonate pathway, may lead to new areas of clinical use for these drugs in the future. 
